Showing 241-250 of 328 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Harnessing insulin signaling in β-cells to counter type 1 diabetes | Joslin Diabetes Center Inc. | Namrata Shukla | Cures | 01-March-2024 to 28-February-2027 | $228,995.00 |
| Targeting RNLS for Type 1 Diabetes Therapy | Joslin Diabetes Center Inc. | Peng Yi | Cures | 01-June-2025 to 31-May-2028 | $1,349,997.00 |
| Evaluating the dose and toxicity of telaprevir in a rat model of T1D | Joslin Diabetes Center Inc. | Rohit Kulkarni | Cures | 01-June-2022 to 31-December-2025 | $494,000.00 |
| Assessing immunotherapeutic potential of a natural IgM antibody for the treatment of T1D | Johns Hopkins University | Abdel Hamad | Cures | 01-June-2024 to 31-January-2026 | $199,881.88 |
| Curing New-Onset Type 1 Diabetes with a Restorative Antibody Therapy | Johns Hopkins University | Dax Fu | Cures | 01-April-2025 to 31-March-2026 | $200,000.00 |
| A Novel Bifunctional Biologic for Type 1 Diabetes | Johns Hopkins University | Giorgio Raimondi | Cures | 01-February-2025 to 31-January-2028 | $995,376.00 |
| REGULATORY ROLE OF CADM1 DURING AUTOIMMUNE DIABETES | Johns Hopkins University | Matthew Poy | Cures | 01-December-2024 to 30-November-2027 | $900,000.00 |
| Towards FDA approval of Autonomous AI for diabetic retinopathy screening in youth | Johns Hopkins University | Risa Wolf | Improving Lives | 01-January-2023 to 31-December-2025 | $637,547.20 |
| A Phase 2 Study Evaluating Short-Term Efficacy of Tonabersat (Xiflam) for Diabetic Macular Edema | Jaeb Center for Health Research | Adam Glassman | Improving Lives | 01-September-2022 to 01-January-2026 | $273,424.00 |
| Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening | Jaeb Center for Health Research | Adam Glassman | Improving Lives | 01-February-2021 to 31-January-2026 | $750,000.00 |